Launch in new window

M.I.A. - Paper Planes

You are here

I/V w/ Research Fellow Malvindar Singh-Bains on Huntington's Disease, possible drug treatments and awards: January 14, 2019

I/V w/ Research Fellow Malvindar Singh-Bains on Huntington's Disease, possible drug treatments and awards: January 14, 2019

I/V w/ Research Fellow Malvindar Singh-Bains on Huntington's Disease, possible drug treatments and awards: January 14, 2019 I/V w/ Research Fellow Malvindar Singh-Bains on Huntington's Disease, possible drug treatments and awards: January 14, 2019, 20.23 MB
Monday, January 14, 2019

Huntington’s is a genetic neurodegenerative disease. About one in every 10,000 people has Huntington’s Disease, but one in 1000 people are affected by its effects. It is caused by an expanded gene in a person’s DNA. Every person has that particular gene, but only some have the mutation. The biggest breakthrough in Huntington’s research occurred in the 90s, but more recently, there has been breakthroughs in regards to possible treatments. Malvindar Singh-Bains is a Research Fellow at the University of Auckland Centre for Brain Research and has had extensive involvement in researching this disease. Lillian Hanly, whose family has the Huntington’s disease, caught up with Malvindar for quite a long chat at the end of last year about her work, Huntington’s research, and possible drug treatments. These drug trials are being considered the biggest breakthrough in terms of the disease since the gene itself was discovered in the 90s.